Erratum

This article refers to:

Retraction: Inhibition of CTCF-Regulated miRNA-185-5p Mitigates Renal Interstitial Fibrosis of Chronic Kidney Disease

Following publication of the Research Article by Melissa Bersanelli, Letizia Gnetti, Elena Varotti, Luca Ampollini, Paolo Carbognani, Francesco Leonardi, Michele Rusca, Nicoletta Campanini, Francesco Ziglioli, Clara I Dadomo, Francesco P Pilato, Alessio Cortellini, Elena Rapacchi, Giuseppe Caruso, Enrico M Silini, Umberto Maestroni & Sebastiano Buti, titled ‘Immune context characterization and heterogeneity in primary tumors and pulmonary metastases from renal cell carcinoma’, which appeared in the January 2019 issue of Immunotherapy (Immunotherapy 11[1], 21–35 [2019]; DOI: 10.2217/imt-2018-0097), it has been brought to our attention that there was an error in Figure 5 and a print error in Table 3.

In Figure 5, labels A and B were lacking and the legends should have read for image A: PD-L1 instead of PD-1; and for image B, PD-L1 RILs M positive and negative instead of PD-1 TILs positive and negative.

The correct figure 5 is shown below:

In Table 3 the three values reported in the first row were misaligned and did not correspond to the relative items as indicated in the first column.

The correct Table 3 is shown below:

Table 3. Quantitative results of the analyzed biomarkers in the study population.

Biomarker	Primary tumor			Pulmonary metastasis
	Tumor cells	TILs	RILs	Tumor cells	TILs	RILs
PD-L1 (% positive cells) Mean Median Range	4.5 0 0–70	5.9 0 0–50	1.3 0 0–25	10.4 0 0–100	5.4 1 0–50	5.9 1 0–60
PD-L1 (No. of cases) Negative + ++ +++	19 5 0 1	16 7 2 0	17 7 0 0	19 3 0 3	11 11 2 1	9 12 3 1
PD-1 (% positive cells) Mean Median Range	-	26.4 20 0–80	24.3 20 0–80	-	18.2 1 0–80	24.9 10 0–80

RIL: Renal-infiltrating lymphocyte; TIL: Tumor-infiltrating lymphocyte.

The authors and editors of Immunotherapy would like to sincerely apologise for any confusion or inconvenience this may have caused our readers.